Speaker Detail

Francois Maisonrouge is a senior managing director in Evercore Partners' advisory business and has 27 years of experience in investment banking. At Evercore, Maisonrouge was involved in advising Bristol-Myers Squibb on its acquisition of Amylin and the sale of half of its interest in Amylin to AstraZeneca; Fenwal on its pending sale to Fresenius; and Terumo on its acquisition of CaridianBCT, Sanofi on its acquisition of Genzyme. Before joining Evercore, Maisonrouge was a managing director and chairman of life sciences at Credit Suisse, where he worked extensively in pharmaceuticals, biotechnology and medical technology. At Credit Suisse, Maisonrouge was responsible for leading the firm's relationships with large health-care clients such as Johnson & Johnson, Schering-Plough, Wyeth, GlaxoSmithKline, Roche and Teva, most notably in executing mergers and acquisitions and capital-raising transactions. Maisonrouge has a master's degree in engineering from Ecole Centrale de Lyon and an M.B.A. from Harvard Business School.